Randomized controlled trialHuman
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
The lancet. HIV, 2019 Dec. Stanley TL, Fourman LT, Feldpausch MN and 16 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The lancet. HIV
Published
2019 Dec
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultAgedDouble-Blind MethodFemaleGrowth Hormone-Releasing HormoneHIV InfectionsHumansLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseTreatment Outcome
Other papers on Tesamorelin
Randomized controlled trial · 2014
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Randomized controlled trial · 2010Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page